NEW YORK (GenomeWeb) – Biocartis today said that it has CE marked its Idylla EGFR Mutation Test for lung cancer, which can now be sold throughout the European Economic Area.

The test enables detection of 51 EGFR mutations directly from one slice of FFPE tissue, which the firm said is in contrast with traditional EGFR testing methods that often require up to six or more tumor slices. The PCR-based test provides results in 2.5 hours and requires less than 2 minutes of hands-on time, according to Biocartis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.